Book Text

REFERENCES

151. Enriquez-Sarano M, Tajik AJ, Schaff HV, et al: Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 90:830–837, 1994.

152. Ramanthan KB, Knowles J, Connor MJ, et al: Natural history of chronic mitral insufficiency: Relation of peak systolic pressure/end-systolic volume ratio to morbidity and mortality. J Am Coll Cardiol 3:1412–1416, 1984.

153. Borow K, Green LH, Mann T, et al: End-systolic volume as a predictor of postoperative left ventricular performance in volume over-load from valvular regurgitation. Am J Med 68:655–663, 1980.

154. Mirsky I, Corin WJ, Murakami T, et al: Correction for preload in assessment of myocardial contractility in aortic and mitral valve disease: Application of the concept of systolic myocardial stiffness. Circulation 78:68–80, 1988.

155. Gott VL, Greene PS, Alejo DE, et al: Replacement of the aortic root in patients with Marfan's syndrome. N Engl J med 340:1307–1313, 1999.

156. Elefteriades JA: Natural history of thoracic aortic aneurysms: Indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 74:S1877–S1880, 2002.

157. Isselbacher EM, Eagle KA, Desanctis RW: Diseases of the aorta. In Braunwald E (ed): Heart Disease. A Textbook of Cardiovascular Medicine, 5th ed. Philadelphia, WB Saunders, 1980, pp 1546–1581.

158. Hirsch J: Reversal of the anticoagulant effects of warfarin by vitamin K₁ . Chest 114:1505–1508, 1998.

159. Schmidt G: Anticoagulants and thrombolytic agents. In Hall JB, Schmidt GA, Woods LA (eds): Principles of Critical Care II. St Louis, McGraw-Hill, 1992, pp 1493–1502.

160. Owen VJ, Burton PB, Michel MC, et al: Myocardial dysfunction in donor hearts. A possible etiology. Circulation 99:2565–2570, 1999.

161. Allard MF, Taylor GP, Wilson JE, McManus BM: Primary cardiac tumors. In Goldhaber SZ, Braunwald E (eds): Cardiopulmonary Diseases and Cardiac Tumors. Atlas of Heart Diseases. Philadelphia, Current Medicine, 1995, pp 15.1–15.22.

162. Reynan K: Frequency of primary tumors of the heart. Am J Cardiol 77:107, 1996.

163. Borden EC, Chip P: Interleukin-6: A cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 123:824, 1994.

164. Seino Y, Ikeda U, Shimada K: Increased expression of interleukin-6 mRNA in cardiac myxomas. Br Heart J 69:565, 1993.

165. Seguin JR, Beigbeder J-Y, Hvass U, et al: Interleukin-6 production by cardiac myxomas may explain constitutional symptoms. J Thorac Cardiovasc Surg 103:599, 1992.

166. Das SK, Brow TD, Pepper J: Continuing controversy in the management of concomitant coronary and carotid disease: An overview. Int J Cardiol 74:47–65, 2000.

167. Zacharias A, Schwann TA, Riordan CJ, et al: Operative and 5-year outcomes of combined carotid and coronary revascularization: Review of a large contemporary experience. Ann Thorac Surg 73:497–498, 2002.

168. Clinical competence in hemodynamic monitoring. A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 15:1460–1464, 1990.

169. Practice guidelines for pulmonary artery catheterization. A report by the American Society of Anesthesiologists Task Force on Pulmonary Artery Catheterization. Anesthesiology 78:380–394, 1993.

170. Pulmonary Artery Catheter Consensus Conference: Consensus statement. Crit Care Med 25:910–925, 1997.

171. Pierson MG, Funk M: Technology versus clinical evaluation for fluid management decisions in CABG patients. Image J Nurs Sci 21:910–924, 1989.

172. Bashein G, Johnson PW, Davis KB, et al: Elective coronary artery bypass surgery without pulmonary artery catheter monitoring. Anesthesiology 63:451–454, 1985.

173. Kaplan JA, Wells PH: Early diagnosis of myocardial ischemia using the pulmonary artery catheter. Anesth Analg 60:789–793, 1981.

174. Sanchez R, Wee M: Perioperative myocardial ischemia: Early diagnosis using the pulmonary artery catheter. J Cardiothorac Vasc Anesth 5:604–607, 1991.

175. van Daele MER, Sutherland G, Mitchell MM, et al: Do changes in pulmonary capillary wedge pressure adequately reflect myocardial ischemia during anesthesia: A correlative perioperative hemodynamic, electrocardiographic and transesophageal echocardiographic study. Circulation 81:865–871, 1990.

176. Moore CH, Lombardo R, Allums JA, et al: Left main coronary artery stenosis: Hemodynamic monitoring to reduce mortality. Ann Thorac Surg 26:445–451, 1978.

177. Truman KJ, McCarthy RJ, Spless BD, et al: Effect of pulmonary artery catheterization on outcome in patients undergoing coronary artery surgery. Anesthesiology 70:199–206, 1989.

178. Pearson KS, Gomez MN, Moyers JR, et al: A cost/benefit analysis on randomized invasive monitoring for patients undergoing cardiac surgery. Anesth Analg 69:336–341, 1989.

179. Hartmann GS, Yao FS, Bruefach M, et al: Severity of aortic atheromatous disease diagnosed by transesophageal echocardiography predicts stroke and other outcomes associated with coronary artery surgery: A prospective study. Anesth Analg 83:701–708, 1996.

180. Royse C, Royse A, Blake D, Grigg L: Screening the thoracic aorta for atheroma: A comparison of manual palpation, transesophageal and epiaortic ultrasonography. Ann Thorac Cardiovasc Surg 4:347–350, 1998.

181. Sologoff S, Keats AS: Randomized trial of primary anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 70:179–188, 1989.

182. Forrest JB, Cahalan MK, Rehder K, et al: Multicenter study of general anesthesia: II: Results. Anesthesiology 72:262–268, 1990.

183. Leung JM, Goehner P, O'Kelly BF, et al: Isoflurane anesthesia and myocardial ischemia: Comparative risk versus sufentanil anesthesia in patients undergoing coronary artery bypass graft surgery. Anesthesiology 74:838–847, 1991.

184. Marty J, Gauzit R, Lefeure P, et al: Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans. Anesth Analg 65:113–119, 1986.

185. Murphy JT, Hall RI, Moffitt EA, et al: Effects of midazolam or sufentanil on coronary hemodynamics after induction and endotracheal intubation in patients undergoing coronary artery bypass graft surgery. Can J Anesth 38:A22, 1991.

186. Cheng DCH, Karski J, Peniston C, et al: Morbidity outcome in early versus conventional tracheal extubation following coronary artery bypass graft (CABG) surgery: A prospective randomized controlled trial. J Thorac Cardiovasc Surg 112:775–764, 1996.

2001

187. Engleman RM, Rousou JA, Flack JE, et al: Fast-track recovery of the coronary bypass patient. Ann Thorac Surg 58:1742–1746, 1994.

188. Westaby S, Pillai R, Parry A, et al: Does modern cardiac surgery require conventional intensive care? Eur J Cardiothorac Surg 7:313–318, 1993.

189. Arom KV, Emery RW, Petersen RJ, et al: Cost-effectiveness and predictors of early extubation. Ann Thorac Surg 60:127–132, 1995.

190. Rolf N, Mollhoff T: Epidural anesthesia for patients undergoing coronary artery bypass grafting. Cur Opin Anesthesiol 10:17–20, 1997.

191. Chaney MA: Intrathecal and epidural anesthesia and analgesia in cardiac surgery. Anesth Analg 84:1211–1221, 1997.

192. Scott NB, Turfrey DJ, Ray DA, et al: A prospective randomized study of the potential benefits of thoracic epidural anesthesia and analgesia in patients undergoing coronary artery bypass grafting. Anesth Analg 93:528–535, 2001.

193. Pastor MC, Sanchez MJ, Casas MA, et al: Thoracic epidural analgesia in coronary artery bypass graft surgery: Seven years' experience. J Cardiothorac Vasc Anesth 17:154–159, 2003.

194. Gravlee GP: Epidural analgesia and coronary artery bypass grafting: The controversy continues. J Cardiothorac Vasc Anesth 17:151–153, 2003.

195. Bull BS, Huse WM, Brauer FS, Korpman RA: Heparin therapy during extracorporeal circulation: II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69:685–689, 1975.

196. Zulys VJ, Teadsdale SJ, Michel ER, et al: Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 71:870–877, 1989.

197. Spiess BD, Gerusheimer T, Vocelka C, et al: Hematologic changes with Ancrod anticoagulated cardiopulmonary bypass: A report. J Cardiothorac Vasc Anesth 10:918–921, 1996.

198. Massomet-Castel S, Pelisser E, Dreyfus G, et al: Low molecular weight heparin in extracorporeal circulation. Lancet 1:1182–1183, 1984.

199. Harrow JC, Van Riper DF, Strong MD, et al: The dose-relationship of tranexamic acid. Anesthesiology 82:383–392, 1995.

200. Vander Salm TJ, Ansell JE, Okike ON: The role of epsilonaminocaproic acid in reducing bleeding after cardiac operation: A double-blind, randomized study. J Thorac Cardiovasc Surg 95:538–552, 1988.

201. DelRossi AJ, Cerraianu AC, Botros S: Prophylactic treatment of post-perfusion bleeding using EACA. Chest 96:27–30, 1989.

202. Harrow JC, Hlavacek J, Strong MD, et al: Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99:77–78, 1990.

203. Leskiw J, Levy JH: Antigeneity of protamine and aprotinin in cardiac surgery. In Pifarre R (ed): Blood Conservation with Aprotinin. Philadelphia, Hanley & Belfus, 1995, pp 253–266.

204. Jaquiss RD, Ghanayem NS, Zacharisen MC, et al: Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation 106(12 Suppl 1):I90–I94, 2002.

205. Dietrich W, Spath P, Zuhlsdorf M, et al: Anaphylactic reactions to aprotinin reexposure in cardiac surgery: Relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 95:64–71, 2001.

206. Sundt TM, Kouchoukos NT, Soffity JE, et al: Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 55:1418–1424, 1993.

207. Mora Mangano CT, Neville MJ, Hsu PH, et al: Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest. Circulation 104:I276–I281, 2001.

208. Spiess BD: Coagulation and cardiopulmonary bypass. In Thys DM (ed): Textbook of Cardiothoracic Anesthesiology. New York, McGraw-Hill, 2001, pp 376–403.

209. Ulker S, McKeown PP, Bayraktutan U: Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res 55:830–837, 2002.

210. Smith PK, Muhlbaier LH: Aprotinin: Safe and effective only with the full-dose regimen. Ann Thorac Surg 62:1575–1577, 1996.

211. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117–123, 1995.

212. Quartin AA, Schein RM, Kett DH, Peduzzi PN: Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277:1058–1063, 1997.

213. Laffey JG, Boylan JF, Cheng DC: The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. Anesthesiology 97:215–252, 2002.

214. Gravlee GP, Davis RF, Kurusz M, Utley JR: Cardiopulmonary Bypass; Principles and Practice, 2nd ed. Philadelphia, Lippincott Williams & Wilkins, 2000.

215. Ledingham SJ, Braimbridge MV, Hearse DJ: The St Thomas' Hospital cardioplegic solution. A comparison of the efficacy of two formulations. J Thorac Cardiovasc Surg 93:240–246, 1987.

216. Chambers DJ, Sakai A, Braimbridge MV, Hearse DJ: Clinical validation of St Thomas' Hospital cardioplegic solution No. 2 (Plegisol). Eur J Cardiothorac Surg 3:346–352, 1989.

217. Gibbon JH: Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37:171–180, 1954.

218. Follette DM, Mulder DG, Maloney JV, Buckberg GD: Advantages of blood cardioplegia over continuous coronary perfusion or intermittent ischemia. Experimental and clinical study. J Thorac Cardiovasc Surg 76:604–619, 1978.

219. Kloner RA, Bolli R, Marban E, et al: Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI workshop. Circulation 97:1848–1867, 1998.

220. Buckberg GD: Left ventricular subendocardial necrosis. Ann Thorac Surg 24:379–393, 1977.

221. Sarnoff SJ, Braunwald E, Welch G: Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension time index. Am J Physiol 192:148, 1958.

222. Buckberg GD: Development of blood cardioplegia and retrograde techniques: The experimenter/observer complex. J Card Surg 13:163–170, 1998.

223. Society of Thoracic Surgeons: US Cardiac Surgery Database T. 1997 CAB only patients. Intraoperative variables. 1999.

224. Teoh KH, Christakis GT, Weisel RD, et al: Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia. J Thorac Cardiovasc Surg 91:888–895, 1986.

225. Kawasuji M, Tomita S, Yasuda T, et al: Myocardial oxygenation during terminal warm blood cardioplegia. Ann Thorac Surg 65:1260–1264, 1998.

226. Barner HB: Blood cardioplegia: A review and comparison with crystalloid cardioplegia. Ann Thorac Surg 52:1354–1367, 1991.

227. Caputo M, Dihmis W, Birdi I, et al: Cardiac troponin T and troponin I release during coronary artery surgery using cold crystalloid and cold blood cardioplegia. Eur J Cardiothorac Surg 12:254–260, 1997.

228. Ibrahim MF, Venn GE, Young CP, Chambers DJ: A clinical comparative study between crystalloid and blood-based St Thomas' hospital cardioplegic solution. Eur J Cardiothorac Surg 15:75–83, 1999.

229. Michenfelder JD, Melde JH: The relationship among canine brain temperature, metabolism, and function during hypothermia. Anesthesiology 75:130–136, 1991.

230. Randomized trial of normo-thermic versus hypothermic coronary bypass surgery. Lancet 343:559–563, 1994.

231. Martin TD, Carver JM, Gott JP, et al: Prospective, randomized trial of retrograde warm blood cardioplegia: Myocardial benefit and neurological threat. Ann Thorac Surg 57:298–302, 1994.

232. Stockard JJ, Bickford RG, Schauble JF: Pressure-dependent cerebral ischemia during cardiopulmonary bypass. Neurology 23:521–529, 1973.

233. Slogoff S, Reul GJ, Keats AS, et al: Role of perfusion pressure and flow in major organ dysfunction after cardiopulmonary bypass. Ann Thorac Surg 50:911–918, 1990.

2002

234. Gold JP, Charlson ME, Williams-Russo P, et al: Improvement of outcomes after coronary artery bypass. A randomized trial comparing intraoperative high versus low mean arterial pressure. J Thorac Cardiovasc Surg 110:1302–1311, discussion 1311–1314, 1995.

235. Boucher JK, Rudy LW Jr, Edmunds LH Jr: Organ blood flow during pulsatile cardiopulmonary bypass. J Appl Physiol 36:86–90, 1974.

236. Philbin DM, Levine FH, Emerson CW, et al: Plasma vasopressin levels and urinary flow during cardiopulmonary bypass in patients with valvular heart disease: Effect of pulsatile flow. J Thorac Cardiovasc Surg 78:779–783, 1979.

237. Mori A, Watanabe K, Onoe M, et al: Regional blood flow in the liver, pancreas and kidney during pulsatile and nonpulsatile perfusion under profound hypothermia. Jpn Circ J 52:219–227, 1988.

238. Olinger GN, Hutchinson LD, Bonchek LI: Pulsatile cardiopulmonary bypass for patients with renal insufficiency. Thorax 38:543–550, 1983.

239. Henze T, Stephan H, Sonntag H: Cerebral dysfunction following extracorporeal circulation for aortocoronary bypass surgery: No differences in neuropsychological outcome after pulsatile versus nonpulsatile flow. Thorac Cardiovasc Surg 38:65–68, 1990.

240. Shaw PJ, Bates D, Cartlidge NE, et al: An analysis of factors predisposing to neurological injury in patients undergoing coronary bypass operations. Q J Med 72:633–646, 1989.

241. Marelli D, Paul A, Samson R, et al: Does the addition of albumin to the prime solution in cardiopulmonary bypass affect clinical outcome? A prospective randomized study. J Thorac Cardiovasc Surg 98:751–756, 1989.

242. Rand PW, Lacomb E, Hunt HE, Austin WH: Viscosity of normal human blood under normothermic and hypothermic conditions. J Appl Physiol 19:117, 1964.

243. Gordon RJ, Kavin MB, Dalcoff GR: Blood rheology. In Thomas CC (ed): Cardiovascular Physiology for Anesthesiologists. Springfield, IL, Charles C Thomas, 1979, pp 27–71.

244. Rahn H, Reeves RB, Howell BJ: Hydrogen ion regulation, temperature, and evolution. Am Rev Respir Dis 112:165–172, 1975.

245. White RN: A comparative physiological approach to hypothermia. J Thorac Cardiovasc Surg 82:821–831, 1981.

246. Hochachka PW: Defense strategies against hypoxia and hypothermia. Science 231:234–241, 1986.

247. Bashein G, Townes BD, Nessly ML, et al: A randomized study of carbon dioxide management during hypothermic cardiopulmonary bypass. Anesthesiology 72:7, 1990.

248. Lance J, Savion N, Smolinsky A, et al: Platelet protection by aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 53:477–481, 1992.

249. Davies LK: Cardiopulmonary bypass in infants and children: How is it different? J Cardiothorac Vasc Anesth 13:330–345, 1999.

250. Kagansky N, Levy S, Knobler H: The role of hyperglycemia in acute stroke. Arch Neurol 58:1209–1212, 2001.

251. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367, 2001.

252. Bull BS, Korpman RA, Huse WM, Briggs BD: Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69:674–684, 1975.

253. Jobes DR, Aitken GL, Shaffer GW: Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110:36–45, 1995.

254. Bovie J, Kemna G: Automated management of heparin anticoagulation in cardiovascular surgery. Proc Am Acad Cardiovasc Perfusion 6:1–10, 1995.

255. Despotis GJ, Joist JH, Hogue J, et al: The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 110:46–54, 1995.

256. Kimmel SE, Sekeres M, Berlin JA, Ellison N: Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 94:1402–1408, 2002.

257. Harrow J: Management of coagulation and bleeding disorders. In Kaplan JA (ed): Cardiac Anesthesia. Philadelphia, WB Saunders, 1983, pp 951–994.

258. Weiss ME, Nyhan D, Peng ZK, et al: Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 320:886–892, 1989.

259. Nuttall GA, Murray MJ, Bowie EJ: Protamine-heparin-induced pulmonary hypertension in pigs: Effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology 74:138–145, 1991.

260. Montalescot G, Lowenstein E, Ogletree ML, et al: Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 82:1765–1777, 1999.

261. Topol EJ: Aspirin with bypass surgery—from taboo to new standard of care. N Engl J Med 347:1359–1360, 2002.

262. Ellison N, Edmunds LH Jr, Colman RW: Platelet aggregation following heparin and protamine administration. Anesthesiology 48:65–68, 1978.

263. Heyns A, Lotter MG, Badenhorst PN, et al: Kinetics and in vivo redistribution of ¹¹¹ indium-labeled human platelets after intravenous protamine sulfate. Thromb Haemost 44:65–71, 1980.

264. Mammen EF, Koets MH, Washington CB, et al: Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 11:281–292, 1985.

265. Boldt J, Zickmann B, Czeke A, et al: Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology 75:426–432, 1991.

266. Despotis GJ, Filos KS, Zoys TN, et al: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 82:13–21, 1996.

267. Murray DJ, Despotis GJ: Coagulation problems. In Thys DM (ed): Textbook of Cardiothoracic Anesthesiology. New York, McGraw-Hill, 2001, pp 982–1010.

268. Despotis GJ, Gravlee GP, Filos KS, Levy JH: Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques. Anesthesiology 91:1122–1151, 1999.

269. Despotis GJ, Joist JH, Goodnough LT: Monitoring hemostasis with cardiac surgery: The impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 43:1684–1696, 1997.

270. Khuri SF, Valeri CR, Loscalzo J, et al: Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 60:1008–1014, 1995.

271. Lu H, Soria C, Commin PL, et al: Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol). Thromb Haemost 66:633–637, 1991.

272. John LC, Rees GM, Kovacs IB: Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 105:816–822, 1993.

273. Akervall N, Fridh L, Schott H, Sollen C: Protamine dosage effects on complement and hemostasis [abstract]. Paper presented at a meeting of the Society of Cardiothoracic Anesthesiologists, 1992, p 268.

274. Stern MP, Shastri K, Raza S, Logue G: Complement activation during cardiopulmonary bypass: The relative role of classical and alternate pathways [abstract]. Paper presented at a meeting of the Society of Cardiothoracic Anesthesiologists, 1991, p 189.

275. Valeri CR, Feingold H, Cassidy G, et al: Hypothermia-induced reversible platelet dysfunction. Ann Surg 205:175–181, 1987.

276. Bashein G, Nessly ML, Rice AL, et al: Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 151:89–93, 1991.

277. Boldt J, Knothe C, Zickmann B, et al: The effects of preoperative aspirin therapy on platelet function in cardiac surgery. Eur J Cardiothorac Surg 6:598–602, 1992.

2003

278. Kallis P, Tooze JA, Talbot S, et al: Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss—a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Eur J Cardiothorac Surg 8:404–409, 1994.

279. Reich DL, Patel GC, Vela-Cantos F, et al: Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg 79:4–8, 1994.

280. Levy JH: Aspirin and bleeding after coronary artery bypass grafting. Anesth Analg 79:1–3, 1994.

281. Tuman KJ, McCarthy RJ, O'Connor CJ, et al: Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg 83:1178–1184, 1996.

282. Hongo RH, Ley J, Dick SE, Yee RR: The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 40:231–237, 2002.

283. Goodnough LT, Johnston MF, Toy PT: The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA 265:86–90, 1991.

284. Smith RC, Leung JM, Mangano DT: Postoperative myocardial ischemia in patients undergoing coronary artery bypass graft surgery. Anesthesiology 74:464–473, 1991.

285. Jain U, Laflamme CJA, Aggarwal A, et al: Electrocardiographic and hemodynamic changes and their association with myocardial infarction during coronary artery bypass surgery. Anesthesiology 86:576–591, 1997.

286. Katz A: Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia, Lippincott Williams & Wilkins, 2000.

287. McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure: Part I. Circulation 105:2099–2106, 2002.

288. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part II: Causal mechanisms and treatment. Circulation 105:1503–1508, 2002.

289. Aurigemma GP, Gottdiener JS, Shemanski L, et al: Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 37:1042–1048, 2001.

290. Dauterman KW, Massie MB, Gheorghiade M: Heart failure associated with preserved systolic function: A common and costly clinical entity. Am Heart J 135(6 Pt 2 Suppl):S310–S319, 1998.

291. Judge KW, Pawitan Y, Caldwell J, et al: Congestive heart failure in patients with preserved left ventricular systolic function: Analysis of the CASS registry. J Am Coll Cardiol 18:377–382, 1991.

292. Brogen WC, Hillis LD, Flores ED, Lange RA: The natural history of isolated left ventricular diastolic dysfunction. Am J Med 92:627–630, 1992.

293. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 103:904–912, 2001.

294. Luscher TF, Enseleit F, Pacher R, et al: Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure. Circulation 106:2666–2672, 2002.

295. Braunwald E: Expanding indications for beta-blockers in heart failure. N Engl J Med 344:1711–1712, 2001.

296. Mills RM, Hobbs RE, Young JB: BNP for heart failure: Role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 8:270–273, 2002.

297. Krumholz HM: β-Blockers for mild to moderate heart failure. Lancet 353:2–3, 1999.

298. Barry WH, Gilbert M: How do β-blockers improve ventricular function in patients with congestive heart failure? Circulation 107:2395–2397, 2003.

299. McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure. Part II. Circulation 105:2223–2228, 2002.

300. Kaul TK, Fields BL: Postoperative acute refractory right ventricular failure: Incidence, pathogenesis, management and prognosis. Cardiovasc Surg 8:1–9, 2000.

301. Kantrowitz A, Tjonneland S, Freed PS, et al: Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA 203:113–118, 1968.

302. Hunt SA, Frazier OH: Mechanical circulatory support and cardiac transplantation. Circulation 97:2079–2090, 1998.

303. Stewart S, Horowitz JD: Home-based intervention in congestive heart failure: Long-term implications on readmission and survival. Circulation 105:2861–2866, 2002.

304. Moser KD, Mann DL: Improving outcomes in heart failure: It's not unusual beyond usual care. Circulation 105:2810–2812, 2002.

305. Delgado DH, Rao V, Ross HJ, et al: Mechanical circulatory assistance: State of art. Circulation 106:2046–2050, 2002.

306. Levin HR, Oz MC, Chen JM, et al: Reversal of chronic ventricular dilatation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 91:2717–2720, 1995.

307. McCarthy PM, Nakatani S, Vargo R, et al: Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 59:609–613, 1995.

308. Dipla K, Mattiello JA, Jeevanandam V, et al: Myocyte recovery after mechanical circulation support in humans with end-stage heart failure. Circulation 97:2316–2322, 1998.

309. Lee SH, Doliba N, Osbakken M, et al: Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 116:344–349, 1998.

310. Heerdt PM, Holmes JW, Cai B, et al: Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102:2713–2719, 2000.

311. Jhaveri R, Conte J: Management of perioperative right ventricular failure. Probl Anesth 13:248–265, 2001.

312. Cooley DA: Initial clinical experience with the Jarvik 2000 implantable axial-flow ventricular assist system. Circulation 105:2808–2809, 2002.

313. Frazier OH, Myers TJ, Gregoric ID, et al: Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 105:2855–2860, 2002.

314. Mathew JP, Parks R, Savino JS, et al: Atrial fibrillation following coronary artery bypass graft surgery. JAMA 276:300–306, 1996.

315. Cresswell LL, Scheussler RB, Rosenbloo M, Cox JL: Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 56:539–549, 1993.

316. Leitch JW, Thomson D, Baird DK, Harris PJ: The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg 100:338–342, 1990.

317. Balser JR: Perioperative arrhythmias: Incidence, risk assessment, evaluation, and management. Card Electrophysiol Rev 6:96–99, 2002.

318. Balser JR, Martinez EA, Winters BD, et al: Beta adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 89:1052–1059, 1989.

319. Brathwaite D, Weissman C: New onset atrial arrhythmias are associated with increased mortality after non-cardiothoracic surgery. Anesthesiology 85:A266, 1996.

320. Moran JL, Gallagher J, Peake SL, et al: Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study. Crit Care Med 23:1816–1824, 1995.

321. Galve E, Rius T, Ballester R, et al: Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 27:1079–1082, 1996.

322. Alfieri O: Surgical treatment of atrial fibrillation: Summary of current experience. Heart Surg Forum 6:103, 2003.

323. Gaita F, Riccardi R, Gallotti R: Surgical approaches to atrial fibrillation. Card Electrophysiol Rev 6:404–405, 2002.

324. Smith RC, Leung JM, Keith FM, et al: Ventricular dysrhythmias in patients undergoing coronary artery bypass graft surgery: Incidence, characteristics, and prognostic importance. Am Heart J 123:73–81, 1992.

325. Kowey PR, Levine JH, Herre JM, et al: Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 92:3255–3263, 1995.

2004

326. Dorian P, Cass D, Schwartz B, et al: Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346:884–890, 2002.

327. Hart JC, Puskas JD, Sabik JF III: Off-pump coronary revascularization: Current state of the art. Semin Thorac Cardiovasc Surg 14:70–81, 2002.

328. van Dijk D, Nierich AP, Jansen EW, et al: Early outcome after off-pump versus on-pump coronary bypass surgery: Results from a randomized study. Circulation 104:1761–1766, 2001.

329. Nathoe HM, van Dijk D, Jansen EW, et al: A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348:394–402, 2003.

330. Rose EA: Off-pump coronary-artery bypass surgery. N Engl J Med 348:379–380, 2003.

331. Yacoub M: Off-pump coronary bypass surgery: In search of an identity. Circulation 104:1743–1745, 2001.

332. Acuff TE, Landreneau RI, Griffith BP, et al: Minimally invasive coronary artery bypass grafting. Ann Thorac Surg 61:135–137, 1996.

333. Calafiroe AM, DiGammarco G, Theodori G, et al: Left anterior descending coronary artery bypass grafting via left anterior small thoracotomy without cardiopulmonary bypass. Ann Thorac Surg 61:1658–1665, 1996.

334. Calafiroe AM, Angelinin GD, Bergsland J, et al: Minimally invasive coronary artery bypass grafting. Ann Thorac Surg 62:1545–1548, 1996.

335. Mehran R, Dangas G, Stamou SC, et al: One-year clinical outcome after minimally invasive direct coronary artery bypass. Circulation 102:2799–2802, 2000.

336. Galloway AC, Ribakove GH, Esposito RA, et al: Post-access MIDCAB: Clinical experience and angiographic follow-up. J Am Coll Cardiol 31:69A, 1998.

337. Robinson NB: Preliminary data indicate no mortality and low morbidity following port-access minimally invasive coronary artery bypass grafting. J Am Coll Cardiol 31:29A, 1998.

338. Toomasian JM, Peters WS, Siegel LC, et al: Extra-corporeal circulation for port-access cardiac surgery. Perfusion 12:83–89, 1997.